Heart & Cardiovascular Protector, Pure Synergy, 60’s

Pure Synergy Heart & Cardiovascular Protector stand out for:

• An antioxidant powerhouse that fosters healthy blood pressure, cholesterol, circulation & vascular health.
• The most vital phytonutrients from the Mediterranean & Okinawan heart healthy diets.
• A research-driven, holistic heart health supplement for long-term cardiovascular care.
• 11 concentrated, organic herbal extracts & enzymes that nourish & support the entire cardiovascular system.
• Concentrated blend of proanthocyanidins, resveratrol, punicalagins, quercetin, hibiscus acids, curcurminoids, hydroxytyrosol, nattokinase & more.
• Made with Organic Ingredients, Non-GMO, Vegan, Gluten-Free.

Heart & Cardiovascular Protector Ingredients: Hawthorn Berry Extract*; Grape Seed Extract*; Japanese Knotweed Extract/Trans-Resveratrol*; Pomegranate Whole Fruit Extract*. Mandarin Orange Extract*; Olive Fruit Extract*; Turmeric Rhizome Extract*; Red Sage Root Extract*; Hibiscus Flower Extract*. Fermented Natto/Nattokinase; Fermented Melon/SOD Enzyme, vegetarian (pullulan) capsule.

Study:

This study shows that different parts of pomegranate may have anti-hypertensive, antioxidant, anti-inflammatory effects and improve lipid profile. From that study: “Patients undergoing maintenance dialysis have a significantly higher incidence of cardiovascular disease (CVD) compared with the general population. CVD is the most common cause of morbidity and mortality among hemodialysis patients, and linked to, among other causes, to increased oxidative stress, inflammation, hypertension and dyslipidemia. Pomegranate, a popular fruit worldwide, has demonstrated health benefits such as antioxidative, antidiabetic, antihypertensive, antihyperlipidemic and anti-inflammatory effects.

In this systematic review of clinical trials, we aim to summarize the effect of different parts of pomegranate and the effects of its use on CVD risk factors in hemodialysis patients. We searched PubMed/MEDLINE, EMBASE, Scopus, and Web of Science to identify eligible clinical trials up to December 2021. Ultimately, seven clinical trials were included in this study. Different parts of pomegranate used in these trials were pomegranate juice, pomegranate extract and pomegranate peel extract. The duration of the studies varied from one dialysis session to 1 year. Our results showed that different parts of pomegranate may have anti-hypertensive, antioxidant, anti-inflammatory effects and improve lipid profile by decreasing TG (triglycerides) and increasing HDL-C (high-density lipoprotein cholesterol) in hemodialysis patients. However, due to limited number of studies, more clinical trials need to be performed.”